US 12,280,108 B2
Vaccines having an antigen and interleukin-21 as an adjuvant
David B. Weiner, Merion, PA (US); and Matthew P. Morrow, Bala Cynwyd, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting (PA)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed on Apr. 15, 2021, as Appl. No. 17/231,534.
Application 17/231,534 is a continuation of application No. 16/181,594, filed on Nov. 6, 2018, granted, now 11,007,265.
Application 16/181,594 is a continuation of application No. 15/514,948, granted, now 10,166,288, previously published as PCT/US2015/052884, filed on Sep. 29, 2015.
Claims priority of provisional application 62/058,304, filed on Oct. 1, 2014.
Prior Publication US 2021/0236631 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61K 39/08 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 41/00 (2020.01); A61K 48/00 (2006.01); A61N 1/32 (2006.01); C07K 14/54 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 39/08 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); A61K 41/0047 (2013.01); A61N 1/327 (2013.01); C07K 14/54 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55527 (2013.01); A61K 48/00 (2013.01); C12N 2740/16134 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
 
1. An immunogenic composition comprising:
a) at least one selected from the group consisting of an antigen and a nucleic acid molecule encoding an antigen,
wherein the antigen is selected from the group consisting of: a human papilloma virus (HPV) antigen or a fragment thereof, an Human Immunodeficiency Virus (HIV) antigen or a fragment thereof, an influenza antigen or a fragment thereof, a Plasmodium falciparum antigen or a fragment thereof, and a C. difficle antigen or a fragment thereof; and
b) a nucleic acid molecule comprising a nucleotide sequence encoding IL-21, wherein IL-21 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence as set forth in SEQ ID NO: 4 and an amino acid sequence that is at least about 90% identical to the entire length of the amino acid sequence as set forth in SEQ ID NO: 4.